A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 23 Feb 2015 Results presented at the 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, according to Teva Pharmaceutical Industries media release.
    • 30 Oct 2014 According to the Teva Pharmaceutical Industries pipeline, company plans to submit a supplemental NDA to the FDA based on results from this study by the end of 2014.
    • 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top